IRLAB publishes prospectus in connection with its listing on Nasdaq Stockholm Main Market
IRLAB Therapeutics AB (“IRLAB” or the “Company”) (IRLAB is currently listed on Nasdaq First North Premier Growth Market under the ticker IRLAB A) announced on September 23, 2020, that Nasdaq Stockholm’s listing committee had approved IRLAB’s application for admission to trading of the Company’s shares of series A on Nasdaq Stockholm Main Market. Today, on September 25, 2020, the prospectus that has been prepared by the Company in connection with the listing was approved and registered by the Swedish Financial Supervisory Authority (“SFSA”) and is now available on IRLAB:s website, www.irlab.se and on SFSA’s website, www.fi.se.
The first day of trading on Nasdaq Stockholm Main Market is expected to be Wednesday, September 30, 2020, and the last day of trading on Nasdaq First North Premier Growth Market is expected to be Tuesday, September 29, 2020.
No new shares will be issued in connection with the list change and the shareholders in IRLAB do not need to take any measures in connection with the list change.
MAQS Advokatbyrå is the Company’s legal advisor in connection with the listing on Nasdaq Stockholm.